NCT
HOME CURRENT ARCHIVE COVID-19
HOME CURRENT ARCHIVE PUBLISH INSTRUCTIONS
FOR AUTHORS COVID-19 LOG IN / REGISTER HISTORY ABOUT US DIRECTORY CONTACT
Diagnosis of tuberculosis: a historical challenge

Rendon, Adrian1; Soto-Moncivais, Berenice1; Lozano-Rodríguez, Brenda Nohemí1





2024, Suplement 1

2024; 83 (S1)






ABSTRACT

KEYWORDS

.

REFERENCES

  1. World Health Organization. Global tuberculosis report 2023. Geneva: WHO; 2023.

  2. Bandala, O. Diagnóstico y pronóstico de la tuberculosis en clínica, por medio de laboratorio. Rev Mex tuberc. 1943;5(1):23-38.

  3. Weyer K. Discovery, innovation, and new frontiers in tuberculosis diagnostics: reflections and expectations. J Infect Dis. 2015;211 Suppl 2:S78-S80. Available in: https://doi.org/10.1093/infdis/jiu822

  4. Kendall EA, Shrestha S, Dowdy DW. The epidemiological importance of subclinical tuberculosis. A critical reappraisal. Am J Respir Crit Care Med. 2021;203(2):168-174. Available in: https://doi.org/10.1164/rccm.202006-2394pp

  5. Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection. Clin Microbiol Rev. 2018;31(4):e00021-18. Available in: https://doi.org/10.1128/cmr.00021-18

  6. Fukushima K, Akagi K, Kondo A, Kubo T, Sakamoto N, Mukae H. First clinical evaluation of the QIAreachTM QuantiFERON-TB for tuberculosis infection and active pulmonary disease. Pulmonology. 2022;28(1):6-12. Available in: https://doi.org/10.1016/j.pulmoe.2021.07.003

  7. Saluzzo F, Mantegani P, Poletti de Chaurand V, Cirillo DM. QIAreach QuantiFERON-TB for the diagnosis of Mycobacterium tuberculosis infection. Eur Respir J. 2022;59(3):2102563. Available in: https://doi.org/10.1183/13993003.02563-2021

  8. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. Tests for Tuberculosis Infection. Geneva: WHO; 2022.

  9. Ho CS, Feng PJI, Narita M, Stout JE, Chen M, Pascopella L, et al. Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study. Lancet Infect Dis. 2022;22(1):85-96. Available in: https://doi.org/10.1016/s1473-3099(21)00145-6

  10. US Preventive Services Task Force. Screening for latent tuberculosis infection in adults: US preventive services task force recommendation statement. JAMA. 2023;329(17):1487-1494. Available in: https://doi.org/10.1001/jama.2023.4899

  11. Dorman S. Advances in the diagnosis of tuberculosis: current status and future prospects. Int J Tuberc Lung Dis. 2015;19(5):504-516. Available in: https://doi.org/10.5588/ijtld.15.0048

  12. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 Update. Geneva: WHO; 2022.

  13. Pai M, Schito M. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. J Infect Dis. 2015;211 Suppl 2:S21-S28. Available in: https://doi.org/10.1093/infdis/jiu803

  14. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005-1015. Available in: https://doi.org/10.1056/nejmoa0907847

  15. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. Geneva: World Health Organization; 2018 (WHO/CDS/TB/2018.19). Licence: CC BY-NCSA 3.0 IGO.

  16. Zhang M, Lu Y, Zhu Y, Wu K, Chen S, Zhou L, et al. Whole-Genome sequencing to predict Mycobacterium tuberculosis drug resistance: A retrospective observational study in Eastern China. Antibiotics (Basel). 2023;12(8):1257. Available in: https://doi.org/10.3390/antibiotics12081257

  17. Melkie ST, Arias L, Farroni C, Makek MJ, Goletti D, Vilaplana C. The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy: a review from the ESGMYC study group. Eur Respir Rev [Internet]. 2022;31(163):210218. Available in: https://doi.org/10.1183/16000617.0218-2021

  18. World Health Organization. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV. Policy update 2019. Geneva: World Health Organization; 2019.

  19. World Health Organization. Chest radiography in tuberculosis detection – summary of current WHO recommendations and guidance on programmatic approaches. Geneva: World Health Organization; 2016 (WHO/HTM/TB/2016.20). ISBN 978 92 4 151150 6.

  20. Silva Miranda M, Breiman A, Allain S, Deknuydt F, Altare F. The tuberculous granuloma: an unsuccessful host defense mechanism providing a safety shelter for the bacteria? Clin Dev Immunol. 2012;2012:139127. Available in: https://doi.org/10.1155/2012/139127

  21. Guo J, Zhang X, Chen X, Cai Y. Proteomics in biomarker discovery for tuberculosis: current status and future perspectives. Front Microbiol. 2022;13:845229. Available in: https://doi.org/10.3389/fmicb.2022.845229

  22. Chaiyachat P, Kaewseekhao B, Chaiprasert A, Kamolwat P, Nonghanphithak D, Phetcharaburanin J, et al. Metabolomic analysis of Mycobacterium tuberculosis reveals metabolic profiles for identification of drug-resistant tuberculosis. Sci Rep. 2023;13(1):8655. Available in: https://doi.org/10.1038/s41598-023-35882-2

  23. Yu Y, Jiang XX, Li JC. Biomarker discovery for tuberculosis using metabolomics. Front Mol Biosci. 2023;10:1099654. Available in: https://doi.org/10.3389/fmolb.2023.1099654

  24. Magdalena D, Michal S, Marta S, Magdalena KP, Anna P, Magdalena G, et al. Targeted metabolomics analysis of serum and Mycobacterium tuberculosis antigen-stimulated blood cultures of pediatric patients with active and latent tuberculosis. Sci Rep. 2022;12(1):4131. Available in: https://doi.org/10.1038/s41598-022-08201-4

  25. World Health Organization. The end TB strategy 2015. Geneva: WHO; 2015.


2024, Suplement 1

2024; 83 (S1)